BrainStorm Q2 FY26 net loss widens to USD 3.9 million; G&A expenses climb to USD 2.7 million
BCLI•Cash position declines
Cash, cash equivalents and restricted cash fell to about USD 200,000 at June 30, from about USD 1.03 million a year earlier.
Q2 net loss widens as expenses rise
BrainStorm Cell Therapeutics posted a Q2 net loss of USD 3.9 million, widening from USD 2.9 million a year earlier.
General and administrative costs climbed to USD 2.7 million from USD 1.5 million; R&D spend edged down to USD 1 million from USD 1.1 million.
Net loss per share was USD (0.35), versus USD (0.34) in the prior-year quarter.
Phase 3b ALS trial enrollment preparation
BrainStorm is preparing to open enrollment for the Phase 3b ENDURANCE trial of NurOwn in ALS under an FDA Special Protocol Assessment.
